Cellular immunotherapy with dendritic cells in cancer: Current status

Alessio Nencioni, Peter Brossart

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Dendritic cells (DCs) are specialized antigen-presenting cells whose immunogenicity leads to the induction of antigen-specific immune responses. DCs can easily be generated ex vivo from peripheral blood monocytes or bone marrow/circulating hematopoietic stem cells cultured in the presence of cytokine cocktails. DCs have been used in numerous clinical trials to induce antitumor immune responses in cancer patients. The studies carried out to date have demonstrated that DCs pulsed with tumor antigens can be safely administered, and this approach produces antigen-specific immune responses. Clinical responses have been observed in a minority of patients. It is likely that either heavy medical pretreatment or the presence of large tumor burdens (or both) is among the causes that impair the benefits of vaccination. Hence, the use of DCs should be considered in earlier stages of disease such as the adjuvant setting. Prospective applications of DCs extend to their use in allogeneic adoptive immunotherapy to specifically target the graft versus tumor reaction. DCs continue to hold promise for cellular immunotherapy, and further investigation is required to determine the clinical settings in which patients will most benefit from the use of this cellular immune adjuvant.

Original languageEnglish
Pages (from-to)501-513
Number of pages13
JournalStem Cells
Volume22
Issue number4
Publication statusPublished - 2004

Fingerprint

Immunotherapy
Dendritic Cells
Neoplasms
Histocompatibility Antigens Class II
Adoptive Immunotherapy
Neoplasm Antigens
Antigen-Presenting Cells
Hematopoietic Stem Cells
Tumor Burden
Monocytes
Vaccination
Bone Marrow
Clinical Trials
Cytokines
Transplants

Keywords

  • Dendritic cells
  • Tumor antigens
  • Vaccinations

ASJC Scopus subject areas

  • Cell Biology

Cite this

Cellular immunotherapy with dendritic cells in cancer : Current status. / Nencioni, Alessio; Brossart, Peter.

In: Stem Cells, Vol. 22, No. 4, 2004, p. 501-513.

Research output: Contribution to journalArticle

Nencioni, Alessio ; Brossart, Peter. / Cellular immunotherapy with dendritic cells in cancer : Current status. In: Stem Cells. 2004 ; Vol. 22, No. 4. pp. 501-513.
@article{9740f796b08943af951acd1122f97970,
title = "Cellular immunotherapy with dendritic cells in cancer: Current status",
abstract = "Dendritic cells (DCs) are specialized antigen-presenting cells whose immunogenicity leads to the induction of antigen-specific immune responses. DCs can easily be generated ex vivo from peripheral blood monocytes or bone marrow/circulating hematopoietic stem cells cultured in the presence of cytokine cocktails. DCs have been used in numerous clinical trials to induce antitumor immune responses in cancer patients. The studies carried out to date have demonstrated that DCs pulsed with tumor antigens can be safely administered, and this approach produces antigen-specific immune responses. Clinical responses have been observed in a minority of patients. It is likely that either heavy medical pretreatment or the presence of large tumor burdens (or both) is among the causes that impair the benefits of vaccination. Hence, the use of DCs should be considered in earlier stages of disease such as the adjuvant setting. Prospective applications of DCs extend to their use in allogeneic adoptive immunotherapy to specifically target the graft versus tumor reaction. DCs continue to hold promise for cellular immunotherapy, and further investigation is required to determine the clinical settings in which patients will most benefit from the use of this cellular immune adjuvant.",
keywords = "Dendritic cells, Tumor antigens, Vaccinations",
author = "Alessio Nencioni and Peter Brossart",
year = "2004",
language = "English",
volume = "22",
pages = "501--513",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Cellular immunotherapy with dendritic cells in cancer

T2 - Current status

AU - Nencioni, Alessio

AU - Brossart, Peter

PY - 2004

Y1 - 2004

N2 - Dendritic cells (DCs) are specialized antigen-presenting cells whose immunogenicity leads to the induction of antigen-specific immune responses. DCs can easily be generated ex vivo from peripheral blood monocytes or bone marrow/circulating hematopoietic stem cells cultured in the presence of cytokine cocktails. DCs have been used in numerous clinical trials to induce antitumor immune responses in cancer patients. The studies carried out to date have demonstrated that DCs pulsed with tumor antigens can be safely administered, and this approach produces antigen-specific immune responses. Clinical responses have been observed in a minority of patients. It is likely that either heavy medical pretreatment or the presence of large tumor burdens (or both) is among the causes that impair the benefits of vaccination. Hence, the use of DCs should be considered in earlier stages of disease such as the adjuvant setting. Prospective applications of DCs extend to their use in allogeneic adoptive immunotherapy to specifically target the graft versus tumor reaction. DCs continue to hold promise for cellular immunotherapy, and further investigation is required to determine the clinical settings in which patients will most benefit from the use of this cellular immune adjuvant.

AB - Dendritic cells (DCs) are specialized antigen-presenting cells whose immunogenicity leads to the induction of antigen-specific immune responses. DCs can easily be generated ex vivo from peripheral blood monocytes or bone marrow/circulating hematopoietic stem cells cultured in the presence of cytokine cocktails. DCs have been used in numerous clinical trials to induce antitumor immune responses in cancer patients. The studies carried out to date have demonstrated that DCs pulsed with tumor antigens can be safely administered, and this approach produces antigen-specific immune responses. Clinical responses have been observed in a minority of patients. It is likely that either heavy medical pretreatment or the presence of large tumor burdens (or both) is among the causes that impair the benefits of vaccination. Hence, the use of DCs should be considered in earlier stages of disease such as the adjuvant setting. Prospective applications of DCs extend to their use in allogeneic adoptive immunotherapy to specifically target the graft versus tumor reaction. DCs continue to hold promise for cellular immunotherapy, and further investigation is required to determine the clinical settings in which patients will most benefit from the use of this cellular immune adjuvant.

KW - Dendritic cells

KW - Tumor antigens

KW - Vaccinations

UR - http://www.scopus.com/inward/record.url?scp=3542999872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3542999872&partnerID=8YFLogxK

M3 - Article

C2 - 15277696

AN - SCOPUS:3542999872

VL - 22

SP - 501

EP - 513

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 4

ER -